Shergill, A., Cecchini, M., Prager, G. W., Cohen, S. A., Kawazoe, A., Wu, S., Desai, K., Aristide, M. R. N., Parikh, A., Vasilopoulos, A., Sui, Y., Sunakawa, Y. (2026). A phase 2 randomized study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with standard of care (SOC) in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps255